THE WOODLANDS, Texas, June 23, 2023 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced plans to advance its investigational drug LX9211 into late-stage development in a clinical program directed towards an application for regulatory approval in diabetic peripheral neuropathic pain, or DPNP. The first late-stage study will be…Read More
Lexicon Pharmaceuticals Announces Planned Advancement of LX9211 Into LateStage Development
